Yahoo Finance

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

–ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in progressive and irreversible vision loss– "Data from our natural history ...
Business Wire

Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression ...
PharmiWeb

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

–Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA– –Changes in visual function, ocular structure and quality of life to be evaluated as ...